April 22, 2021
Business News

Oncodesign Records Positive Profitability for the Second Straight Year and Doubles Its Operating Profit Within the Context of the Global Health Crisis

DIJON, France–()–Regulatory News:

ONCODESIGN (ALONC – FR0011766229) (Paris:ALONC), a biopharmaceutical group specialized in precision medicine, announces its FY 2020 financial results and its outlook for 2021 and beyond.

Philippe GENNE, Oncodesign’s Chairman and Chief Executive, says: “Oncodesign has not only proven its resilience and the strength of its economic model, the Company has also shown its agility, its ingenuity and its determination within the context of an unprecedented global public health crisis. Oncodesign has been able to cope with the challenges of a turbulent 2020, generating revenue of €25.5 million, similar to the figure recorded in 2019 – a record year that had seen growth of…

Click here to view the original article.

Related Posts

You might also like ...

Universal Hydrogen Announces $20.5M in Series A Funding to Build and Test Full-Scale Hardware for Hydrogen Commercial Aircraft
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors
AON Splash Image
ScienceMedia Launches SMi TrialD: The World’s First Mobile Education Platform for Decentralized Clinical Trials